JP2021516671A5 - - Google Patents
Info
- Publication number
- JP2021516671A5 JP2021516671A5 JP2020543914A JP2020543914A JP2021516671A5 JP 2021516671 A5 JP2021516671 A5 JP 2021516671A5 JP 2020543914 A JP2020543914 A JP 2020543914A JP 2020543914 A JP2020543914 A JP 2020543914A JP 2021516671 A5 JP2021516671 A5 JP 2021516671A5
- Authority
- JP
- Japan
- Prior art keywords
- itr
- sequence
- seq
- rbg
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191314A JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2026018445A JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632775P | 2018-02-20 | 2018-02-20 | |
| US62/632,775 | 2018-02-20 | ||
| US201862663532P | 2018-04-27 | 2018-04-27 | |
| US62/663,532 | 2018-04-27 | ||
| PCT/US2019/018640 WO2019164854A1 (en) | 2018-02-20 | 2019-02-19 | Compositions for treatment of wet age-related macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191314A Division JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021516671A JP2021516671A (ja) | 2021-07-08 |
| JP2021516671A5 true JP2021516671A5 (enExample) | 2022-02-24 |
Family
ID=67688300
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2026018445A Pending JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2026018445A Pending JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12558434B2 (enExample) |
| EP (1) | EP3755804A4 (enExample) |
| JP (3) | JP2021516671A (enExample) |
| KR (1) | KR20210022524A (enExample) |
| AU (2) | AU2019223963A1 (enExample) |
| CA (1) | CA3090293A1 (enExample) |
| IL (1) | IL276777B2 (enExample) |
| MA (1) | MA51916A (enExample) |
| SG (1) | SG11202007252VA (enExample) |
| WO (1) | WO2019164854A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018130284A1 (en) * | 2017-01-12 | 2018-07-19 | Telefonaktiebolaget Lm Ericsson (Publ) | Anomaly detection of media event sequences |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US11360969B2 (en) | 2019-03-20 | 2022-06-14 | Promethium, Inc. | Natural language based processing of data stored across heterogeneous data sources |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| BR112022017182A2 (pt) * | 2020-02-28 | 2022-11-08 | Univ Pennsylvania | Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas |
| EP4138918B1 (en) * | 2020-04-24 | 2026-07-22 | Siemens Healthcare Diagnostics Inc. | Calibration and quality control reagents for use with immunoassays for antibodies |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| KR20230088630A (ko) | 2020-10-16 | 2023-06-20 | 자이로스코프 테라퓨틱스 리미티드 | 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도 |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| WO2023014892A1 (en) * | 2021-08-04 | 2023-02-09 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| KR102789747B1 (ko) * | 2021-12-29 | 2025-04-03 | 한국과학기술원 | Prox1 단백질에 중화 활성을 갖는 결합 분자 |
| AR128422A1 (es) * | 2022-02-02 | 2024-05-08 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| IL134643A0 (en) | 1997-08-27 | 2001-04-30 | Ariad Gene Therapeutics Inc | Chimeric transcriptional activators and compositions and uses related thereto |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CA2388432A1 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| US20020068694A1 (en) | 2000-07-26 | 2002-06-06 | Jeltsch Markku Michael | Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| HUE024877T2 (en) | 2007-10-30 | 2016-02-29 | Genentech Inc | Antibody purification by cation exchange chromatography |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20130090375A1 (en) | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| BR112015021036A2 (pt) | 2013-03-15 | 2017-10-10 | Univ Pennsylvania | composições e métodos para tratar mps1 |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US11555059B2 (en) | 2014-04-25 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | LDLR variants and their use in compositions for reducing cholesterol levels |
| CR20160519A (es) | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| EP3344294A4 (en) | 2015-08-31 | 2019-03-20 | The Trustees Of The University Of Pennsylvania | CHIMERIC AAV ANTI-VEGF FOR THE TREATMENT OF CANCER IN DOGS |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CN108778330A (zh) | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| EP4667578A3 (en) | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
-
2019
- 2019-02-18 US US16/971,215 patent/US12558434B2/en active Active
- 2019-02-19 CA CA3090293A patent/CA3090293A1/en active Pending
- 2019-02-19 IL IL276777A patent/IL276777B2/en unknown
- 2019-02-19 AU AU2019223963A patent/AU2019223963A1/en not_active Abandoned
- 2019-02-19 SG SG11202007252VA patent/SG11202007252VA/en unknown
- 2019-02-19 JP JP2020543914A patent/JP2021516671A/ja active Pending
- 2019-02-19 MA MA051916A patent/MA51916A/fr unknown
- 2019-02-19 WO PCT/US2019/018640 patent/WO2019164854A1/en not_active Ceased
- 2019-02-19 KR KR1020207026455A patent/KR20210022524A/ko not_active Ceased
- 2019-02-19 EP EP19757101.1A patent/EP3755804A4/en active Pending
-
2023
- 2023-11-09 JP JP2023191314A patent/JP2024016207A/ja active Pending
-
2025
- 2025-06-25 AU AU2025204780A patent/AU2025204780A1/en active Pending
-
2026
- 2026-02-06 JP JP2026018445A patent/JP2026090364A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518427A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| JP2022153418A5 (enExample) | ||
| JP2025000642A5 (enExample) | ||
| JP2020114218A5 (enExample) | ||
| JP2022552262A5 (enExample) | ||
| JP2020510430A5 (enExample) | ||
| JP2021503914A5 (enExample) | ||
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| JP7685070B2 (ja) | 血管新生に関連する眼疾患の処置のための組成物および方法 | |
| US20240148903A1 (en) | Delivery of antibody by using dual viral vector system | |
| US20240279680A1 (en) | Retinal Disorders | |
| JP2023545229A5 (enExample) | ||
| US20220389120A1 (en) | Multispecific antagonists | |
| AU2024322589A1 (en) | Compositions and methods for expressing therapeutics | |
| US20250074974A1 (en) | Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof | |
| Robert et al. | Antibody delivery mediated by recombinant adeno-associated virus for the treatment of various chronic and infectious diseases | |
| US20250375536A1 (en) | Vector | |
| WO2025133635A1 (en) | Therapies for preventing or treating inflammatory eye disease | |
| HK40105223A (en) | An expression cassette suitable for adalimumab and its vector and application | |
| WO2025093734A1 (en) | Bispecific antigen binding protein with fviii mimetic activity | |
| JP2024525186A (ja) | 網膜障害 | |
| HK40110067A (en) | Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof |